Status: Recruiting
Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity
A multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of IBI362 in participants with mild to moderate hypertension complicated by overweight/obesity who have not received antihypertensive drug treatment
Participants needed: 336
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Innovent Biologics (Suzhou) Co. Ltd.Updated: May 27, 2026Locations: 1
Eligibility criteria
Aged ≥ 18 years old at the time of signing the informed consent form. [+3]
The investigator suspects that the participant may be allergic to the components... [+9]